AnaptysBio Inc (ANAB)
22.15
+0.98
(+4.63%)
USD |
NASDAQ |
Nov 22, 15:13
AnaptysBio Shareholders Equity (Quarterly): 84.37M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 84.37M |
| June 30, 2024 | 9.879M |
| March 31, 2024 | 47.78M |
| December 31, 2023 | 88.10M |
| September 30, 2023 | 120.38M |
| June 30, 2023 | 148.45M |
| March 31, 2023 | 191.09M |
| December 31, 2022 | 262.10M |
| September 30, 2022 | 277.62M |
| June 30, 2022 | 304.31M |
| March 31, 2022 | 330.75M |
| December 31, 2021 | 356.43M |
| September 30, 2021 | 383.61M |
| June 30, 2021 | 385.73M |
| March 31, 2021 | 381.94M |
| December 31, 2020 | 396.73M |
| September 30, 2020 | 360.24M |
| June 30, 2020 | 381.44M |
| March 31, 2020 | 400.56M |
| December 31, 2019 | 405.01M |
| Date | Value |
|---|---|
| September 30, 2019 | 420.89M |
| June 30, 2019 | 448.42M |
| March 31, 2019 | 468.16M |
| December 31, 2018 | 486.36M |
| September 30, 2018 | 499.68M |
| June 30, 2018 | 284.98M |
| March 31, 2018 | 294.53M |
| December 31, 2017 | 307.58M |
| September 30, 2017 | 101.36M |
| June 30, 2017 | 109.18M |
| March 31, 2017 | 110.12M |
| December 31, 2016 | 39.27M |
| September 30, 2016 | 44.76M |
| June 30, 2016 | 44.40M |
| March 31, 2016 | 41.78M |
| December 31, 2015 | 42.34M |
| September 30, 2015 | 45.58M |
| June 30, 2015 | 5.853M |
| December 31, 2014 | 5.993M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
9.879M
Minimum
Jun 2024
405.01M
Maximum
Dec 2019
265.83M
Average
317.53M
Median
Shareholders Equity (Quarterly) Benchmarks
| Eli Lilly and Co | 14.24B |
| Regeneron Pharmaceuticals Inc | 29.33B |
| Ligand Pharmaceuticals Inc | 841.18M |
| Agios Pharmaceuticals Inc | 1.627B |
| ADMA Biologics Inc | 231.89M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 493.42M |
| Total Liabilities (Quarterly) | 409.05M |
| Current Ratio | 10.23 |